Docoh
Loading...

NAOV NanoVibronix

NanoVibronix, Inc. is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company's primary products include PainShield®, UroShield® and WoundShield®, all of which are portable devices suitable for administration at home without assistance of medical professionals.

NAOV stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

16 Aug 21
17 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 5.67M 5.67M 5.67M 5.67M 5.67M 5.67M
Cash burn (monthly) 768.67K 28.69M 330.33K 697.42K 638.67K 406.92K
Cash used (since last report) 2.77M 103.25M 1.19M 2.51M 2.3M 1.46M
Cash remaining 2.91M -97.57M 4.48M 3.16M 3.37M 4.21M
Runway (months of cash) 3.8 -3.4 13.6 4.5 5.3 10.3

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Dec 20 Stephen Russell Brown Option to Purchase Common Stock Common Stock Grant Acquire A No No 0.84 50,000 42K 50,000
22 Dec 20 Thomas Mika Option to Purchase Common Stock Common Stock Grant Acquire A No No 0.84 90,000 75.6K 90,000
22 Dec 20 Christopher M Fashek Option to Purchase Common Stock Common Stock Grant Acquire A No No 0.84 120,000 100.8K 120,000
22 Dec 20 Brian M Murphy Option to Purchase Common Stock Common Stock Grant Acquire A No No 0.84 200,000 168K 200,000
22 Dec 20 Martin M Goldstein Option to Purchase Common Stock Common Stock Grant Acquire A No No 0.84 60,000 50.4K 60,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

17.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 19 17 +11.8%
Opened positions 2 14 -85.7%
Closed positions 0 0
Increased positions 5 0 NEW
Reduced positions 4 0 NEW
13F shares
Current Prev Q Change
Total value 3.29M 3.53M -6.8%
Total shares 4.18M 4.24M -1.3%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Packer Paul 1.67M $1.28M 0.0%
Hirschman Orin 771.46K $589K 0.0%
Alpha Capital Anstalt 645.72K $493K 0.0%
Vanguard 308.92K $263K +61.2%
AFSIP Amtrust Financial Services 146.15K $124K 0.0%
Geode Capital Management 136.88K $116K +37.7%
Citadel Advisors 99.85K $85K -27.4%
HighTower Advisors 92.55K $79K 0.0%
Renaissance Technologies 85.21K $73K -73.2%
VIRT Virtu Financial 65.05K $55K +24.9%
Largest transactions
Shares Bought/sold Change
Renaissance Technologies 85.21K -233.29K -73.2%
Vanguard 308.92K +117.24K +61.2%
STT State Street 41.59K +41.59K NEW
Citadel Advisors 99.85K -37.74K -27.4%
Geode Capital Management 136.88K +37.5K +37.7%
UBS UBS Group AG - Registered Shares 26.25K -28.67K -52.2%
NTRS Northern Trust 46.87K +27.83K +146.1%
VIRT Virtu Financial 65.05K +12.98K +24.9%
Two Sigma Advisers 20.5K +5.5K +36.7%
BAC Bank Of America 9 +9 NEW

Financial report summary

?
Management Discussion
  • Revenues. For the twelve months ended December 31, 2020 and 2019, our revenues were approximately $623,000 and $530,000, respectively, an increase of approximately 18%, or $93,000, between the periods. The increase was mainly attributable to increased sales from adding distributors. Our revenues may fluctuate as we add new customers or when existing distributors make large purchases of our products during one period and no purchases during another period. Our revenues by quarter may not be linear or consistent. We do not anticipate that our revenues will be impacted by inflation or changing prices in the foreseeable future.
  • For the twelve months ended December 31, 2020, the percentage of revenues attributable to our products was: PainShield – 92%; WoundShield – 8%; and UroShield – 0%. For the twelve months ended December 31, 2019, the percentage of revenues attributable to our products was: PainShield – 67% and UroShield – 33%. For the twelve months ended December 31, 2020 and 2019, the percentage of revenues attributable to our disposable products was 5% and 4.5%, respectively. For the twelve months ended December 31, 2020 and 2019, the portion of our revenues that was derived from distributors was 93% and 67.5%, respectively.
  • Gross Profit. For the twelve months ended December 31, 2020 and 2019, gross profit was approximately $214,000 and $281,000, respectively, despite the increase in sales mainly due to larger royalty revenues in 2019 and a large sale to a distributor at little margin.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: charged, confirmation, contractor, dismissed, earlier, essentially, final, greater, Incorporation, issuable, larger, overhead, proposal, repurchase, resolution, solicited, timeline
Removed: apply, approach, attempted, convert, earliest, existed, extension, hearing, lessee, measure, modified, Panel, present, recognize, retrospective, transition, ultimate